{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:46:42Z","timestamp":1770310002884,"version":"3.49.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"crossref","award":["RCBS20221008093314036"],"award-info":[{"award-number":["RCBS20221008093314036"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06753-3","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:03:46Z","timestamp":1768442626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unraveling the many faces of angioimmunoblastic T-cell lymphoma: clinical, pathological, and molecular heterogeneity"],"prefix":"10.1007","volume":"105","author":[{"given":"Jia-Ping","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-Yuan","family":"Xian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Song","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"1","key":"6753_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/nejm197501022920101","volume":"292","author":"RJ Lukes","year":"1975","unstructured":"Lukes RJ, Tindle BH (1975) Immunoblastic lymphadenopathy. A hyperimmune entity resembling hodgkin\u2019s disease. N Engl J Med 292(1):1\u20138. https:\/\/doi.org\/10.1056\/nejm197501022920101","journal-title":"N Engl J Med"},{"issue":"35","key":"6753_CR2","first-page":"1246","volume":"104","author":"K Lennert","year":"1979","unstructured":"Lennert K (1979) [Nature, prognosis and nomenclature of angioimmunoblastic (lymphadenopathy (lymphogranulomatosis X or T-zone lymphoma)]. Dtsch Med Wochenschr 104(35):1246\u20131247","journal-title":"Dtsch Med Wochenschr"},{"issue":"7866","key":"6753_CR3","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/s0140-6736(74)90553-4","volume":"1","author":"G Frizzera","year":"1974","unstructured":"Frizzera G, Moran EM, Rappaport H (1974) Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet 1(7866):1070\u20131073. https:\/\/doi.org\/10.1016\/s0140-6736(74)90553-4","journal-title":"Lancet"},{"issue":"2","key":"6753_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood.V72.2.413.413","volume":"72","author":"Y Kaneko","year":"1988","unstructured":"Kaneko Y et al (1988) Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive angioimmunoblastic lymphadenopathy with dysproteinemia-type features. Blood 72(2):413\u2013421","journal-title":"Blood"},{"issue":"3","key":"6753_CR5","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1182\/blood.V72.3.1000.bloodjournal7231000","volume":"72","author":"K Tobinai","year":"1988","unstructured":"Tobinai K et al (1988) Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma. Blood 72(3):1000\u20131006","journal-title":"Blood"},{"issue":"11","key":"6753_CR6","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L de Leval","year":"2007","unstructured":"de Leval L et al (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109(11):4952\u20134963. https:\/\/doi.org\/10.1182\/blood-2006-10-055145","journal-title":"Blood"},{"issue":"1","key":"6753_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc1111708","volume":"366","author":"L Couronn\u00e9","year":"2012","unstructured":"Couronn\u00e9 L, Bastard C, Bernard OA (2012) TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 366(1):95\u201396. https:\/\/doi.org\/10.1056\/NEJMc1111708","journal-title":"N Engl J Med"},{"issue":"8","key":"6753_CR8","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","volume":"119","author":"RA Cairns","year":"2012","unstructured":"Cairns RA et al (2012) IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119(8):1901\u20131903. https:\/\/doi.org\/10.1182\/blood-2011-11-391748","journal-title":"Blood"},{"issue":"2","key":"6753_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M et al (2014) Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46(2):171\u2013175. https:\/\/doi.org\/10.1038\/ng.2872","journal-title":"Nat Genet"},{"issue":"7","key":"6753_CR10","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"25","key":"6753_CR11","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/jco.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124\u20134130. https:\/\/doi.org\/10.1200\/jco.2008.16.4558","journal-title":"J Clin Oncol"},{"issue":"3","key":"6753_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","volume":"20","author":"SM Horwitz","year":"2022","unstructured":"Horwitz SM et al (2022) Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(3):285\u2013308. https:\/\/doi.org\/10.6004\/jnccn.2022.0015. T-Cell Lymphomas","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"6753_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1200\/jco.2008.12.6219","volume":"26","author":"C Kyriakou","year":"2008","unstructured":"Kyriakou C et al (2008) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 26(2):218\u2013224. https:\/\/doi.org\/10.1200\/jco.2008.12.6219","journal-title":"J Clin Oncol"},{"key":"6753_CR14","doi-asserted-by":"publisher","first-page":"1382189","DOI":"10.3389\/fimmu.2024.1382189","volume":"15","author":"W Fulati","year":"2024","unstructured":"Fulati W et al (2024) Consolidation therapy with autologous stem cell transplantation after remission of induction chemotherapy prolongs the survival of patients with peripheral T-cell lymphoma. Front Immunol 15:1382189. https:\/\/doi.org\/10.3389\/fimmu.2024.1382189","journal-title":"Front Immunol"},{"issue":"1","key":"6753_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1182\/hematology.2024000670","volume":"2024","author":"P Dreger","year":"2024","unstructured":"Dreger P, Schmitz N (2024) The role of stem cell transplant (auto and allo) in PTCL and CTCL. Hematol Am Soc Hematol Educ Program 2024(1):69\u201377. https:\/\/doi.org\/10.1182\/hematology.2024000670","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"6753_CR16","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","volume":"129","author":"MA Lunning","year":"2017","unstructured":"Lunning MA, Vose JM (2017) Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood 129(9):1095\u20131102. https:\/\/doi.org\/10.1182\/blood-2016-09-692541","journal-title":"Blood"},{"issue":"2","key":"6753_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1200\/jco.2011.37.3647","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M et al (2013) Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 31(2):240\u2013246. https:\/\/doi.org\/10.1200\/jco.2011.37.3647","journal-title":"J Clin Oncol"},{"issue":"9","key":"6753_CR18","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","volume":"100","author":"L de Leval","year":"2015","unstructured":"de Leval L et al (2015) Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica 100(9):e361. https:\/\/doi.org\/10.3324\/haematol.2015.126300","journal-title":"Haematologica"},{"issue":"12","key":"6753_CR19","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2011-08-374371","volume":"119","author":"T Tokunaga","year":"2012","unstructured":"Tokunaga T et al (2012) Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 119(12):2837\u20132843. https:\/\/doi.org\/10.1182\/blood-2011-08-374371","journal-title":"Blood"},{"issue":"3","key":"6753_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood.2020010387","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH et al (2021) Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell project. Blood 138(3):213\u2013220. https:\/\/doi.org\/10.1182\/blood.2020010387","journal-title":"Blood"},{"issue":"6","key":"6753_CR21","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.3390\/curroncol28060456","volume":"28","author":"MF Mohammed Saleh","year":"2021","unstructured":"Mohammed Saleh MF et al (2021) Recent advances in diagnosis and therapy of angioimmunoblastic T cell lymphoma. Curr Oncol 28(6):5480\u20135498. https:\/\/doi.org\/10.3390\/curroncol28060456","journal-title":"Curr Oncol"},{"issue":"9","key":"6753_CR22","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","volume":"111","author":"N Mourad","year":"2008","unstructured":"Mourad N et al (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the groupe d\u2019etude des lymphomes de l\u2019adulte (GELA) trials. Blood 111(9):4463\u20134470. https:\/\/doi.org\/10.1182\/blood-2007-08-105759","journal-title":"Blood"},{"issue":"4","key":"6753_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/pas.0000000000002355","volume":"49","author":"FJ de la D\u00edaz","year":"2025","unstructured":"de la D\u00edaz FJ et al (2025) Clinical, Pathologic, and molecular spectrum of angioinmmunoblastic T-cell lymphoma cutaneous lesions: Clinical, Pathologic, and molecular analysis. Am J Surg Pathol 49(4):403\u2013410. https:\/\/doi.org\/10.1097\/pas.0000000000002355","journal-title":"Am J Surg Pathol"},{"issue":"20","key":"6753_CR24","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH et al (2016) The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"6753_CR25","doi-asserted-by":"publisher","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med, (1993) 329(14): p. 987\u2013994.https:\/\/doi.org\/10.1056\/nejm199309303291402","DOI":"10.1056\/nejm199309303291402"},{"issue":"7","key":"6753_CR26","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474\u20132479. https:\/\/doi.org\/10.1182\/blood-2003-09-3080","journal-title":"Blood"},{"issue":"4","key":"6753_CR27","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1002\/cam4.5248","volume":"12","author":"C Wei","year":"2023","unstructured":"Wei C et al (2023) Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China. Cancer Med 12(4):3987\u20133998. https:\/\/doi.org\/10.1002\/cam4.5248","journal-title":"Cancer Med"},{"issue":"11","key":"6753_CR28","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1080\/10428194.2023.2235043","volume":"64","author":"EWY Chang","year":"2023","unstructured":"Chang EWY et al (2023) Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study. Leuk Lymphoma 64(11):1782\u20131791. https:\/\/doi.org\/10.1080\/10428194.2023.2235043","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"6753_CR29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z et al (2014) An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837\u2013842. https:\/\/doi.org\/10.1182\/blood-2013-09-524108","journal-title":"Blood"},{"key":"6753_CR30","doi-asserted-by":"publisher","first-page":"1580370","DOI":"10.3389\/fonc.2025.1580370","volume":"15","author":"QY Xiang","year":"2025","unstructured":"Xiang QY et al (2025) Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China. Front Oncol 15:1580370. https:\/\/doi.org\/10.3389\/fonc.2025.1580370","journal-title":"Front Oncol"},{"issue":"8","key":"6753_CR31","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1007\/s10238-023-01197-9","volume":"23","author":"Q Zhang","year":"2023","unstructured":"Zhang Q et al (2023) Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma. Clin Exp Med 23(8):4219\u20134235. https:\/\/doi.org\/10.1007\/s10238-023-01197-9","journal-title":"Clin Exp Med"},{"issue":"6","key":"6753_CR32","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/PAS.0b013e3182785610","volume":"37","author":"A Nicolae","year":"2013","unstructured":"Nicolae A et al (2013) Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin\/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol 37(6):816\u2013826. https:\/\/doi.org\/10.1097\/PAS.0b013e3182785610","journal-title":"Am J Surg Pathol"},{"key":"6753_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12082001","author":"A Satou","year":"2022","unstructured":"Satou A, Takahara T, Tsuzuki T (2022) <Emphasis Type=\"Italic\">Pathological and molecular features of nodal peripheral T-cell lymphomas.<\/Emphasis>. Diagnostics (Basel). https:\/\/doi.org\/10.3390\/diagnostics12082001","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"6753_CR34","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/PAS.0b013e31802d68e9","volume":"31","author":"AD Attygalle","year":"2007","unstructured":"Attygalle AD et al (2007) Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol 31(7):1077\u20131088. https:\/\/doi.org\/10.1097\/PAS.0b013e31802d68e9","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"6753_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajcp\/aqab090","volume":"156","author":"Y Xie","year":"2021","unstructured":"Xie Y, Jaffe ES (2021) How i diagnose angioimmunoblastic T-Cell lymphoma. Am J Clin Pathol 156(1):1\u201314. https:\/\/doi.org\/10.1093\/ajcp\/aqab090","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"6753_CR36","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","volume":"34","author":"S Chiba","year":"2020","unstructured":"Chiba S, Sakata-Yanagimoto M (2020) Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia 34(10):2592\u20132606. https:\/\/doi.org\/10.1038\/s41375-020-0990-y","journal-title":"Leukemia"},{"issue":"1","key":"6753_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/hon.2080","volume":"32","author":"A Singh","year":"2014","unstructured":"Singh A et al (2014) Peripheral blood sCD3\u207b CD4\u207a T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma. Hematol Oncol 32(1):16\u201321. https:\/\/doi.org\/10.1002\/hon.2080","journal-title":"Hematol Oncol"},{"issue":"1","key":"6753_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3324\/haematol.2023.284448","volume":"110","author":"P Stephan","year":"2025","unstructured":"Stephan P et al (2025) Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets. Haematologica 110(1):129\u2013141. https:\/\/doi.org\/10.3324\/haematol.2023.284448","journal-title":"Haematologica"},{"issue":"2","key":"6753_CR39","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1182\/blood.v99.2.627","volume":"99","author":"A Attygalle","year":"2002","unstructured":"Attygalle A et al (2002) Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 99(2):627\u2013633. https:\/\/doi.org\/10.1182\/blood.v99.2.627","journal-title":"Blood"},{"issue":"1","key":"6753_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/PAS.0b013e31820065c9","volume":"35","author":"DM Dorfman","year":"2011","unstructured":"Dorfman DM, Shahsafaei A (2011) <Emphasis Type=\"Italic\">CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma.<\/Emphasis>. Am J Surg Pathol 35(1):76\u201383. https:\/\/doi.org\/10.1097\/PAS.0b013e31820065c9","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"6753_CR41","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3324\/haematol.2009.010991","volume":"95","author":"T Marafioti","year":"2010","unstructured":"Marafioti T et al (2010) The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica 95(3):432\u2013439. https:\/\/doi.org\/10.3324\/haematol.2009.010991","journal-title":"Haematologica"},{"issue":"10","key":"6753_CR42","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1158\/1078-0432.Ccr-22-2955","volume":"29","author":"JC Chavez","year":"2023","unstructured":"Chavez JC et al (2023) Targeting the inducible T-cell costimulator (ICOS) in patients with Relapsed\/Refractory T-follicular helper phenotype peripheral T-cell and angioimmunoblastic T-cell lymphoma. Clin Cancer Res 29(10):1869\u20131878. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-2955","journal-title":"Clin Cancer Res"},{"key":"6753_CR43","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.biopha.2016.10.083","volume":"84","author":"S Eivazi","year":"2016","unstructured":"Eivazi S et al (2016) Development of T follicular helper cells and their role in disease and immune system. Biomed Pharmacother 84:1668\u20131678. https:\/\/doi.org\/10.1016\/j.biopha.2016.10.083","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"6753_CR44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1053\/j.semdp.2011.03.003","volume":"28","author":"P Gaulard","year":"2011","unstructured":"Gaulard P, de Leval L (2011) Follicular helper T cells: implications in neoplastic hematopathology. Semin Diagn Pathol 28(3):202\u2013213. https:\/\/doi.org\/10.1053\/j.semdp.2011.03.003","journal-title":"Semin Diagn Pathol"},{"issue":"1","key":"6753_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.7150\/jca.37033","volume":"11","author":"J Qian","year":"2020","unstructured":"Qian J et al (2020) High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center. J Cancer 11(1):57\u201368. https:\/\/doi.org\/10.7150\/jca.37033","journal-title":"J Cancer"},{"key":"6753_CR46","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2709270","author":"J Du","year":"2022","unstructured":"Du J et al (2022) <Emphasis Type=\"Italic\">Spatial transcriptomics analysis reveals that CCL17 and CCL22 are robust indicators of a suppressive immune environment in angioimmunoblastic T cell lymphoma (AITL).<\/Emphasis>. Front Biosci Landmark. https:\/\/doi.org\/10.31083\/j.fbl2709270","journal-title":"Front Biosci Landmark"},{"issue":"1","key":"6753_CR47","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41408-024-01199-0","volume":"14","author":"M Zhu","year":"2024","unstructured":"Zhu M et al (2024) Single-cell transcriptomic and Spatial analysis reveal the immunosuppressive microenvironment in relapsed\/refractory angioimmunoblastic T-cell lymphoma. Blood Cancer J 14(1):218. https:\/\/doi.org\/10.1038\/s41408-024-01199-0","journal-title":"Blood Cancer J"},{"issue":"1","key":"6753_CR48","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4143\/crt.2017.476","volume":"51","author":"JH Liang","year":"2019","unstructured":"Liang JH et al (2019) The prognostic role of Circulating Epstein-Barr virus DNA copy number in angioimmunoblastic T-Cell lymphoma treated with Dose-Adjusted EPOCH. Cancer Res Treat 51(1):150\u2013157. https:\/\/doi.org\/10.4143\/crt.2017.476","journal-title":"Cancer Res Treat"},{"issue":"3","key":"6753_CR49","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00277-020-04389-5","volume":"100","author":"Q Zhu","year":"2021","unstructured":"Zhu Q et al (2021) Novel tumour-infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de Novo angioimmunoblastic T cell lymphoma. Ann Hematol 100(3):715\u2013723. https:\/\/doi.org\/10.1007\/s00277-020-04389-5","journal-title":"Ann Hematol"},{"issue":"7569","key":"6753_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature15252","volume":"525","author":"Q Zhang","year":"2015","unstructured":"Zhang Q et al (2015) Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525(7569):389\u2013393. https:\/\/doi.org\/10.1038\/nature15252","journal-title":"Nature"},{"issue":"1","key":"6753_CR51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.19746\/j.cnki.issn.1009-2137.2025.01.015","volume":"33","author":"HB Wang","year":"2025","unstructured":"Wang HB, Wang XJ, Guo XH (2025) Clinical characteristics and prognosis analysis of angioimmunoblastic T-cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 33(1):108\u2013113. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2025.01.015","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"9","key":"6753_CR52","doi-asserted-by":"publisher","first-page":"270","DOI":"10.31083\/j.fbl2709270","volume":"27","author":"J Du","year":"2022","unstructured":"Du J et al (2022) Spatial transcriptomics analysis reveals that CCL17 and CCL22 are robust indicators of a suppressive immune environment in angioimmunoblastic T cell lymphoma (AITL). Front Biosci (Landmark Ed) 27(9):270. https:\/\/doi.org\/10.31083\/j.fbl2709270","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"2","key":"6753_CR53","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41375-023-02093-7","volume":"38","author":"S Suma","year":"2024","unstructured":"Suma S et al (2024) Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution. Leukemia 38(2):340\u2013350. https:\/\/doi.org\/10.1038\/s41375-023-02093-7","journal-title":"Leukemia"},{"issue":"11","key":"6753_CR54","doi-asserted-by":"publisher","first-page":"102147","DOI":"10.1016\/j.labinv.2024.102147","volume":"104","author":"TP Sainz","year":"2024","unstructured":"Sainz TP et al (2024) Role of the crosstalk b:neoplastic T follicular helper cells in the pathobiology of nodal T follicular helper cell lymphomas. Lab Invest 104(11):102147. https:\/\/doi.org\/10.1016\/j.labinv.2024.102147","journal-title":"Lab Invest"},{"key":"6753_CR55","doi-asserted-by":"publisher","first-page":"1125503","DOI":"10.3389\/fimmu.2023.1125503","volume":"14","author":"AC Betzler","year":"2023","unstructured":"Betzler AC, Ushmorov A, Brunner C (2023) The transcriptional program during germinal center reaction - a close view at GC B cells, Tfh cells and Tfr cells. Front Immunol 14:1125503. https:\/\/doi.org\/10.3389\/fimmu.2023.1125503","journal-title":"Front Immunol"},{"issue":"18","key":"6753_CR56","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1182\/blood.2022015451","volume":"140","author":"M Fujisawa","year":"2022","unstructured":"Fujisawa M et al (2022) Clonal germinal center B cells function as a niche for T-cell lymphoma. Blood 140(18):1937\u20131950. https:\/\/doi.org\/10.1182\/blood.2022015451","journal-title":"Blood"},{"issue":"8","key":"6753_CR57","doi-asserted-by":"publisher","first-page":"e","DOI":"10.1016\/j.heliyon.2023.e18836","volume":"9","author":"S Zhu","year":"2023","unstructured":"Zhu S et al (2023) Immune infiltration and drug specificity analysis of different subtypes based on functional status in angioimmunoblastic T-cell lymphoma. Heliyon 9(8):e. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18836","journal-title":"Heliyon"},{"issue":"9","key":"6753_CR58","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.27736","volume":"100","author":"A Bouska","year":"2025","unstructured":"Bouska A et al (2025) Integrative genomic and transcriptomic analysis reveals targetable vulnerabilities in angioimmunoblastic T-Cell lymphoma. Am J Hematol 100(9):1486\u20131501. https:\/\/doi.org\/10.1002\/ajh.27736","journal-title":"Am J Hematol"},{"key":"6753_CR59","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.cellbio.21.020604.150721","volume":"21","author":"AB Jaffe","year":"2005","unstructured":"Jaffe AB, Hall A (2005) Rho gtpases: biochemistry and biology. Annu Rev Cell Dev Biol 21:247\u2013269. https:\/\/doi.org\/10.1146\/annurev.cellbio.21.020604.150721","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"9","key":"6753_CR60","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","volume":"132","author":"SY Ng","year":"2018","unstructured":"Ng SY et al (2018) RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood 132(9):935\u2013947. https:\/\/doi.org\/10.1182\/blood-2017-11-818617","journal-title":"Blood"},{"issue":"2","key":"6753_CR61","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","volume":"33","author":"JR Cortes","year":"2018","unstructured":"Cortes JR et al (2018) RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell 33(2):259\u2013273. https:\/\/doi.org\/10.1016\/j.ccell.2018.01.001","journal-title":"Cancer Cell"},{"issue":"5","key":"6753_CR62","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/bjh.19089","volume":"203","author":"C Zhang","year":"2023","unstructured":"Zhang C et al (2023) Angioimmunoblastic T-cell lymphoma: novel recurrent mutations and prognostic biomarkers by cell-free DNA profiling. Br J Haematol 203(5):807\u2013819. https:\/\/doi.org\/10.1111\/bjh.19089","journal-title":"Br J Haematol"},{"issue":"5","key":"6753_CR63","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/leu.2015.357","volume":"30","author":"J Rohr","year":"2016","unstructured":"Rohr J et al (2016) Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia 30(5):1062\u20131070. https:\/\/doi.org\/10.1038\/leu.2015.357","journal-title":"Leukemia"},{"key":"6753_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153716","author":"X Liu","year":"2022","unstructured":"Liu X et al (2022) <Emphasis Type=\"Italic\">Mutations affecting genes in the proximal T-cell receptor signaling pathway in peripheral T-cell lymphoma.<\/Emphasis>. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14153716","journal-title":"Cancers (Basel)"},{"key":"6753_CR65","doi-asserted-by":"publisher","unstructured":"Shen X et al (2024) [Mutation characteristics of angioimmunoblastic T-cell lymphoma: an analysis of 75 cases]. Zhonghua Bing Li Xue Za Zhi, 53(1): pp. 29\u201333.https:\/\/doi.org\/10.3760\/cma.j.cn112151-20230823-00089","DOI":"10.3760\/cma.j.cn112151-20230823-00089"},{"issue":"8","key":"6753_CR66","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.it.2024.06.004","volume":"45","author":"MF Neurath","year":"2024","unstructured":"Neurath MF, Berg LJ (2024) VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases. Trends Immunol 45(8):580\u2013596. https:\/\/doi.org\/10.1016\/j.it.2024.06.004","journal-title":"Trends Immunol"},{"issue":"3","key":"6753_CR67","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/leu.2017.273","volume":"32","author":"M Fujisawa","year":"2018","unstructured":"Fujisawa M et al (2018) Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia 32(3):694\u2013702. https:\/\/doi.org\/10.1038\/leu.2017.273","journal-title":"Leukemia"},{"issue":"1","key":"6753_CR68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","volume":"20","author":"C Quivoron","year":"2011","unstructured":"Quivoron C et al (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20(1):25\u201338. https:\/\/doi.org\/10.1016\/j.ccr.2011.06.003","journal-title":"Cancer Cell"},{"issue":"1","key":"6753_CR69","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1038\/bcj.2016.122","volume":"7","author":"TB Nguyen","year":"2017","unstructured":"Nguyen TB et al (2017) Identification of cell-type-specific mutations in nodal T-cell lymphomas. Blood Cancer J 7(1):e516. https:\/\/doi.org\/10.1038\/bcj.2016.122","journal-title":"Blood Cancer J"},{"issue":"1","key":"6753_CR70","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13046-024-03179-5","volume":"43","author":"A Krug","year":"2024","unstructured":"Krug A et al (2024) In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma. J Exp Clin Cancer Res 43(1):262. https:\/\/doi.org\/10.1186\/s13046-024-03179-5","journal-title":"J Exp Clin Cancer Res"},{"issue":"13","key":"6753_CR71","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","volume":"49","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser F et al (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent Lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 49(13):2869\u20132876. https:\/\/doi.org\/10.1016\/j.ejca.2013.04.029","journal-title":"Eur J Cancer"},{"issue":"2","key":"6753_CR72","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","volume":"5","author":"F Lemonnier","year":"2021","unstructured":"Lemonnier F et al (2021) Integrative analysis of a phase 2 trial combining Lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv 5(2):539\u2013548. https:\/\/doi.org\/10.1182\/bloodadvances.2020003081","journal-title":"Blood Adv"},{"issue":"19","key":"6753_CR73","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1182\/bloodadvances.2023009767","volume":"7","author":"J Ruan","year":"2023","unstructured":"Ruan J et al (2023) Multicenter phase 2 study of Romidepsin plus Lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Adv 7(19):5771\u20135779. https:\/\/doi.org\/10.1182\/bloodadvances.2023009767","journal-title":"Blood Adv"},{"issue":"26","key":"6753_CR74","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ et al (2021) A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood 138(26):2828\u20132837. https:\/\/doi.org\/10.1182\/blood.2021013379","journal-title":"Blood"},{"issue":"1","key":"6753_CR75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s1470-2045(23)00589-2","volume":"25","author":"Y Song","year":"2024","unstructured":"Song Y et al (2024) Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 part B): a single-arm, multinational, phase 2 study. Lancet Oncol 25(1):117\u2013125. https:\/\/doi.org\/10.1016\/s1470-2045(23)00589-2","journal-title":"Lancet Oncol"},{"issue":"6","key":"6753_CR76","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1080\/10428194.2025.2455489","volume":"66","author":"SM Horwitz","year":"2025","unstructured":"Horwitz SM et al (2025) Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase\/janus kinase inhibitor, in relapsed\/refractory peripheral T-cell lymphoma. Leuk Lymphoma 66(6):1100\u20131110. https:\/\/doi.org\/10.1080\/10428194.2025.2455489","journal-title":"Leuk Lymphoma"},{"key":"6753_CR77","doi-asserted-by":"publisher","first-page":"1301437","DOI":"10.3389\/fonc.2023.1301437","volume":"13","author":"Z Li","year":"2023","unstructured":"Li Z, Guo W, Bai O (2023) Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas. Front Oncol 13:1301437. https:\/\/doi.org\/10.3389\/fonc.2023.1301437","journal-title":"Front Oncol"},{"issue":"19","key":"6753_CR78","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","volume":"124","author":"C Bossard","year":"2014","unstructured":"Bossard C et al (2014) Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood 124(19):2983\u20132986. https:\/\/doi.org\/10.1182\/blood-2014-07-584953","journal-title":"Blood"},{"issue":"8","key":"6753_CR79","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","volume":"98","author":"E Sabattini","year":"2013","unstructured":"Sabattini E et al (2013) CD30 expression in peripheral T-cell lymphomas. Haematologica 98(8):e81\u2013e82. https:\/\/doi.org\/10.3324\/haematol.2013.084913","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"6753_CR80","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1182\/blood-2024-204718","volume":"144","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024) <Emphasis Type=\"Italic\">Brentuximab vedotin-based treatment in patients with CD30-positive lymphoma: a retrospective analysis.<\/Emphasis>. Blood 144(Supplement 1):6465\u20136465. https:\/\/doi.org\/10.1182\/blood-2024-204718","journal-title":"Blood"},{"issue":"10168","key":"6753_CR81","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S et al (2019) Brentuximab Vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393(10168):229\u2013240. https:\/\/doi.org\/10.1016\/s0140-6736(18)32984-2","journal-title":"Lancet"},{"issue":"14","key":"6753_CR82","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1182\/bloodadvances.2023012531","volume":"8","author":"M Brink","year":"2024","unstructured":"Brink M et al (2024) Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands cancer registry. Blood Adv 8(14):3619\u20133628. https:\/\/doi.org\/10.1182\/bloodadvances.2023012531","journal-title":"Blood Adv"},{"issue":"1","key":"6753_CR83","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M et al (2022) Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer 21(1):28. https:\/\/doi.org\/10.1186\/s12943-021-01489-2","journal-title":"Mol Cancer"},{"issue":"3","key":"6753_CR84","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ccell.2019.07.008","volume":"36","author":"L Mondrag\u00f3n","year":"2019","unstructured":"Mondrag\u00f3n L et al (2019) GAPDH overexpression in the T cell lineage promotes angioimmunoblastic T cell lymphoma through an NF-\u03baB-Dependent mechanism. Cancer Cell 36(3):268\u2013287. https:\/\/doi.org\/10.1016\/j.ccell.2019.07.008","journal-title":"Cancer Cell"},{"issue":"7","key":"6753_CR85","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1182\/blood.2023020244","volume":"142","author":"MH Merrill","year":"2023","unstructured":"Merrill MH et al (2023) A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma. Blood 142(7):621\u2013628. https:\/\/doi.org\/10.1182\/blood.2023020244","journal-title":"Blood"},{"issue":"7","key":"6753_CR86","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A et al (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie innovative Nei Linfomi) prospective multicenter trial. Blood 110(7):2316\u20132323. https:\/\/doi.org\/10.1182\/blood-2007-02-074641","journal-title":"Blood"},{"issue":"11","key":"6753_CR87","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00277-013-1880-4","volume":"92","author":"C Binder","year":"2013","unstructured":"Binder C et al (2013) CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. Ann Hematol 92(11):1521\u20131528. https:\/\/doi.org\/10.1007\/s00277-013-1880-4","journal-title":"Ann Hematol"},{"issue":"7","key":"6753_CR88","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","volume":"22","author":"HC Kluin-Nelemans","year":"2011","unstructured":"Kluin-Nelemans HC et al (2011) Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 22(7):1595\u20131600. https:\/\/doi.org\/10.1093\/annonc\/mdq635","journal-title":"Ann Oncol"},{"issue":"18","key":"6753_CR89","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1182\/blood.2022018254","volume":"141","author":"J Ruan","year":"2023","unstructured":"Ruan J et al (2023) Multicenter phase 2 study of oral Azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood 141(18):2194\u20132205. https:\/\/doi.org\/10.1182\/blood.2022018254","journal-title":"Blood"},{"issue":"16","key":"6753_CR90","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L et al (2021) Combined oral 5-azacytidine and Romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 137(16):2161\u20132170. https:\/\/doi.org\/10.1182\/blood.2020009004","journal-title":"Blood"},{"issue":"19","key":"6753_CR91","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","volume":"4","author":"P Ghione","year":"2020","unstructured":"Ghione P et al (2020) T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma. Blood Adv 4(19):4640\u20134647. https:\/\/doi.org\/10.1182\/bloodadvances.2020002396","journal-title":"Blood Adv"},{"issue":"21","key":"6753_CR92","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","volume":"132","author":"F Lemonnier","year":"2018","unstructured":"Lemonnier F et al (2018) Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood 132(21):2305\u20132309. https:\/\/doi.org\/10.1182\/blood-2018-04-840538","journal-title":"Blood"},{"issue":"3","key":"6753_CR93","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/jco.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E et al (2022) Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-Cell lymphoma: results of the Ro-CHOP phase III study (Conducted by LYSA). J Clin Oncol 40(3):242\u2013251. https:\/\/doi.org\/10.1200\/jco.21.01815","journal-title":"J Clin Oncol"},{"issue":"4","key":"6753_CR94","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hon.2320","volume":"35","author":"B Pro","year":"2017","unstructured":"Pro B et al (2017) Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol 35(4):914\u2013917. https:\/\/doi.org\/10.1002\/hon.2320","journal-title":"Hematol Oncol"},{"issue":"1","key":"6753_CR95","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40001-025-02326-8","volume":"30","author":"W Zhang","year":"2025","unstructured":"Zhang W et al (2025) Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies. Eur J Med Res 30(1):69. https:\/\/doi.org\/10.1186\/s40001-025-02326-8","journal-title":"Eur J Med Res"},{"issue":"8","key":"6753_CR96","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y et al (2015) Results from a multicenter, open-label, pivotal phase II study of Chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26(8):1766\u20131771. https:\/\/doi.org\/10.1093\/annonc\/mdv237","journal-title":"Ann Oncol"},{"issue":"1","key":"6753_CR97","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y et al (2017) Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol 10(1):69. https:\/\/doi.org\/10.1186\/s13045-017-0439-6","journal-title":"J Hematol Oncol"},{"issue":"12","key":"6753_CR98","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/s1470-2045(24)00502-3","volume":"25","author":"D Maruyama","year":"2024","unstructured":"Maruyama D et al (2024) Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. Lancet Oncol 25(12):1589\u20131601. https:\/\/doi.org\/10.1016\/s1470-2045(24)00502-3","journal-title":"Lancet Oncol"},{"issue":"12","key":"6753_CR99","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/s1470-2045(24)00503-5","volume":"25","author":"PL Zinzani","year":"2024","unstructured":"Zinzani PL et al (2024) Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 25(12):1602\u20131613. https:\/\/doi.org\/10.1016\/s1470-2045(24)00503-5","journal-title":"Lancet Oncol"},{"key":"6753_CR100","doi-asserted-by":"publisher","first-page":"1070660","DOI":"10.3389\/fimmu.2022.1070660","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang Z et al (2022) Safety and efficacy of dual PI3K-\u03b4, \u03b3 inhibitor, Duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials. Front Immunol 13:1070660. https:\/\/doi.org\/10.3389\/fimmu.2022.1070660","journal-title":"Front Immunol"},{"issue":"4","key":"6753_CR101","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.annonc.2020.12.009","volume":"32","author":"HY Yhim","year":"2021","unstructured":"Yhim HY et al (2021) Combination treatment of Copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): an open-label phase I\/II trial. Ann Oncol 32(4):552\u2013559. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.009","journal-title":"Ann Oncol"},{"issue":"20","key":"6753_CR102","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1158\/1078-0432.Ccr-24-1194","volume":"30","author":"J Jin","year":"2024","unstructured":"Jin J et al (2024) A phase Ib study of linperlisib in the treatment of patients with relapsed and\/or refractory peripheral T-cell lymphoma. Clin Cancer Res 30(20):4593\u20134600. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1194","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6753_CR103","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/10428194.2020.1837796","volume":"62","author":"TD Rodgers","year":"2021","unstructured":"Rodgers TD et al (2021) Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. Leuk Lymphoma 62(3):598\u2013605. https:\/\/doi.org\/10.1080\/10428194.2020.1837796","journal-title":"Leuk Lymphoma"},{"key":"6753_CR104","doi-asserted-by":"publisher","first-page":"104404","DOI":"10.1016\/j.critrevonc.2024.104404","volume":"200","author":"M Sirico","year":"2024","unstructured":"Sirico M et al (2024) Navigating the complexity of PI3K\/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond. Crit Rev Oncol Hematol 200:104404. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104404","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"6753_CR105","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","volume":"30","author":"SM Horwitz","year":"2024","unstructured":"Horwitz SM et al (2024) Duvelisib plus Romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial. Nat Med 30(9):2517\u20132527. https:\/\/doi.org\/10.1038\/s41591-024-03076-6","journal-title":"Nat Med"},{"issue":"Suppl10","key":"6753_CR106","doi-asserted-by":"publisher","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","volume":"30","author":"SE Nunnery","year":"2019","unstructured":"Nunnery SE, Mayer IA (2019) Management of toxicity to isoform \u03b1-specific PI3K inhibitors. Ann Oncol 30(Suppl10):x21\u2013x. https:\/\/doi.org\/10.1093\/annonc\/mdz440","journal-title":"Ann Oncol"},{"issue":"6","key":"6753_CR107","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1111\/bjh.20063","volume":"206","author":"MN Sorial","year":"2025","unstructured":"Sorial MN et al (2025) Forecasting optimal treatments in relapsed\/refractory mature T- and NK-cell lymphomas: A global PETAL consortium study. Br J Haematol 206(6):1664\u20131677. https:\/\/doi.org\/10.1111\/bjh.20063","journal-title":"Br J Haematol"},{"issue":"5","key":"6753_CR108","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.26499","volume":"97","author":"Y Wang","year":"2022","unstructured":"Wang Y et al (2022) Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial. Am J Hematol 97(5):623\u2013629. https:\/\/doi.org\/10.1002\/ajh.26499","journal-title":"Am J Hematol"},{"key":"6753_CR109","doi-asserted-by":"publisher","first-page":"175883592092382","DOI":"10.1177\/1758835920923829","volume":"12","author":"Y Sun","year":"2020","unstructured":"Sun Y et al (2020) Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients. Ther Adv Med Oncol 12:1758835920923829. https:\/\/doi.org\/10.1177\/1758835920923829","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"6753_CR110","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13148-023-01436-6","volume":"15","author":"J Chen","year":"2023","unstructured":"Chen J et al (2023) Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK\/T-cell lymphoma to Chidamide. Clin Epigenetics 15(1):19. https:\/\/doi.org\/10.1186\/s13148-023-01436-6","journal-title":"Clin Epigenetics"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06753-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06753-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06753-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:34:04Z","timestamp":1770262444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06753-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6753"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06753-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}